PF-03622905
Modify Date: 2024-04-05 13:03:24
PF-03622905 structure
|
Common Name | PF-03622905 | ||
|---|---|---|---|---|
| CAS Number | 1072100-15-2 | Molecular Weight | 469.58 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C24H35N7O3 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of PF-03622905PF-03622905 is a potent and ATP-competitive PKC inhibitor with IC50s of 5.6 nM, 14.5 nM, 13 nM, 37.7 nM, and 74.1 nM for PKCα, PKCβI, PKCβII, PKCγ, and PKCθ, respectively. PF-03622905 shows high specificity for PKC over other protein kinases[1]. |
| Name | PF-03622905 |
|---|
| Description | PF-03622905 is a potent and ATP-competitive PKC inhibitor with IC50s of 5.6 nM, 14.5 nM, 13 nM, 37.7 nM, and 74.1 nM for PKCα, PKCβI, PKCβII, PKCγ, and PKCθ, respectively. PF-03622905 shows high specificity for PKC over other protein kinases[1]. |
|---|---|
| Related Catalog | |
| Target |
PKCα:5.6 nM (IC50) PKCβI:14.5 nM (IC50) PKCβII:13 nM (IC50) PKCγ:37.7 nM (IC50) PKCθ:74.1 nM (IC50) |
| In Vitro | PF-03622905 causes concentration-dependent inhibition of phospho-ERK1/2 formation, interleukin 8 release, and phospho-SHP2 levels with an IC50 value 0.15 μM, 0.16 μM, and 35 nM, respectively[1]. PF-03622905 shows low cytotoxicity at 1 μM against human umbilical vein endothelial cells with remaining cell viability at 83.3% viable[1]. |
| References |
| Molecular Formula | C24H35N7O3 |
|---|---|
| Molecular Weight | 469.58 |